Information Provided By:
Fly News Breaks for July 10, 2017
NVDQ, SYK, ZBH
Jul 10, 2017 | 08:14 EDT
RBC Capital analyst Glenn Novarro prefers Zimmer Biomet (ZBH) over Stryker (SYK) heading into Q2 results. The analyst says that Zimmer's stock can rise if the company's meets Q2 consensus estimates and maintains its guidance. The analyst says that Stryker's ability to beat 2017 EPS estimates will be "limited" by its Novadaq (NVDQ) acqusition and its investments. However, the analyst recommends buying Stryker on pullbacks.
News For ZBH;SYK;NVDQ From the Last 2 Days
SYK
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.